<?xml version="1.0" encoding="UTF-8"?>
<p id="p0028" num="0028" sourceFile="EPÂ 1511718B1.xml">The compounds of formula I are, as already mentioned above, monoamine oxidase B inhibitors and can be used for the treatment or prevention of diseases in which MAO-B inhibitors might be beneficial. These include acute and chronic neurological disorders, cognitive disorders and memory deficits. Treatable neurological disorders are for instance traumatic or chronic degenerative processes of the nervous system, such as Alzheimer's disease, other types of dementia, minimal cognitive impairment or Parkinson's disease. Other indications include psychiatric diseases such as depression, anxiety, panic attack, social phobia, schizophrenia, eating and metabolic disorders such as obesity as well as the prevention and treatment of withdrawal syndromes induced by abuse of alcohol, nicotine and other addictive drugs. Other treatable indications may be reward deficiency syndrome (G.M. Sullivan, International patent application No. 
  <patcit id="pcit0001" dnum="WO0134172A2">
    <text>WO 01/34172 A2</text>
  </patcit>), peripheral neuropathy caused by cancer chemotherapy (G. Bobotas, International Patent Application No. 
  <patcit id="pcit0002" dnum="WO9733572A1">
    <text>WO 97/33572 A1</text>
  </patcit>), or the treatment of multiple sclerosis (R.Y. Harris, International patent application No. 
  <patcit id="pcit0003" dnum="WO9640095A1">
    <text>WO 96/40095 A1</text>
  </patcit>) and other neuroinflammatory diseases.
</p>
